NEEDLE AND SYRINGE PROGRAMS NEEDED IN PRISONS TO PREVENT SPREAD OF HEPATITIS B AND C

AMA Position Statement on Blood Borne Viruses 2017

The AMA has called for needle and syringe programs (NSPs) to be introduced in prisons and other custodial settings, to reduce the spread of Blood Borne Viruses (BBVs) including hepatitis B and C, and HIV.

AMA President, Dr Michael Gannon, said today that prevalence of BBVs is significantly higher in prisons, yet custodial facilities provide a unique opportunity to protect the health of inmates.

Launching the AMA Position Statement on Blood Borne Viruses 2017, Dr Gannon said that with new BBV treatments, including hepatitis C direct acting antivirals, available on the subsidised Pharmaceutical Benefits Scheme (PBS), now is the time to identify people with undiagnosed BBVs.

“BBVs are a major health problem in our prisons, which is no surprise given that many people are in custody for drug-related offences in the first place,” Dr Gannon said.

“BBVs may be transmitted through infected blood, exposure to contaminated drug products, unsterile injecting practices, sexual contact, failures in infection control in health care, mother to child transmission, and unsterile tattooing or body piercing practices.

“All the evidence shows that harm minimisation measures, such as access to condoms and lubricant, regulated needle and syringe programs, and access to disinfectants such as bleach, protects not just those in custody, but prison staff too.

“It also reduces the likelihood of someone being discharged from prison with an untreated BBV, and spreading it in the outside community.

“The AMA supports NSPs as a frontline approach to preventing BBVs. Prison-based NSP trials have been shown to reduce the risk of needle-stick injuries to staff, and increase the number of detainees accessing drug treatment, while showing no adverse effect on illicit drug use or overall prison security.”

The AMA Position Statement also calls for greater emphasis on prevention, reliable and affordable screening, immunisation, and treatment, with stronger referral pathways, and greater investment in specialist services.

It also warns against making transmission of a BBV a crime, arguing the BBVs are first and foremost a health issue, not a legal one.

“Criminal sanctions should be used only as a last resort for people who intentionally put others at risk of BBV infection,” Dr Gannon said.

“There is no evidence that laws that criminalise BBV transmission either prevent or deter transmission.
“Indeed, such laws can be a barrier to the prevention and management of BBVs by discouraging sex workers and injecting drug users from being tested and treated, or from disclosing their diagnosis.

“Doctors are at the front line of BBV diagnosis and treatment, and should therefore be well informed about legal issues, particularly their own legal obligations, to provide the best advice and support to individual patients.”

The AMA Position Statement also calls for specific resourcing and management of HLTV-1, a relatively unknown BBV that affects Aboriginal people in central Australia.


9 January 2017

CONTACT: John Flannery 02 6270 5477 / 0419 494 761
Maria Hawthorne 02 6270 5478 / 0427 209 753

Follow the AMA Media on Twitter: http://twitter.com/ama_media
Follow the AMA President on Twitter: http://twitter.com/amapresident
Follow Australian Medicine on Twitter: https://twitter.com/amaausmed
Like the AMA on Facebook https://www.facebook.com/AustralianMedicalAssociation